ATE428785T1 - Aktive und inactive cc-chemokinrezeptoren und nukleinsäuremoleküle, die für diesen rezeptor kodieren - Google Patents

Aktive und inactive cc-chemokinrezeptoren und nukleinsäuremoleküle, die für diesen rezeptor kodieren

Info

Publication number
ATE428785T1
ATE428785T1 AT04018812T AT04018812T ATE428785T1 AT E428785 T1 ATE428785 T1 AT E428785T1 AT 04018812 T AT04018812 T AT 04018812T AT 04018812 T AT04018812 T AT 04018812T AT E428785 T1 ATE428785 T1 AT E428785T1
Authority
AT
Austria
Prior art keywords
inactive
receptor
code
active
nucleic acid
Prior art date
Application number
AT04018812T
Other languages
English (en)
Inventor
Michel Samson
Gilbert Vassart
Marc Parmentier
Frederique Libert
Original Assignee
Euroscreen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26144381&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE428785(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euroscreen Sa filed Critical Euroscreen Sa
Application granted granted Critical
Publication of ATE428785T1 publication Critical patent/ATE428785T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
AT04018812T 1996-03-01 1997-02-28 Aktive und inactive cc-chemokinrezeptoren und nukleinsäuremoleküle, die für diesen rezeptor kodieren ATE428785T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96870021 1996-03-01
EP96870102 1996-08-06

Publications (1)

Publication Number Publication Date
ATE428785T1 true ATE428785T1 (de) 2009-05-15

Family

ID=26144381

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04018812T ATE428785T1 (de) 1996-03-01 1997-02-28 Aktive und inactive cc-chemokinrezeptoren und nukleinsäuremoleküle, die für diesen rezeptor kodieren
AT97904948T ATE280826T1 (de) 1996-03-01 1997-02-28 Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT97904948T ATE280826T1 (de) 1996-03-01 1997-02-28 Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen

Country Status (10)

Country Link
US (6) US6448375B1 (de)
EP (4) EP0883687B1 (de)
JP (2) JP4117904B2 (de)
AT (2) ATE428785T1 (de)
CA (1) CA2247989C (de)
DE (2) DE69731373T2 (de)
DK (2) DK0883687T3 (de)
ES (2) ES2227672T3 (de)
PT (1) PT883687E (de)
WO (1) WO1997032019A2 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US20040151719A1 (en) * 1995-06-06 2004-08-05 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US6261763B1 (en) * 1995-06-07 2001-07-17 Progenics Pharmaceuticals, Inc. Fluorescence resonance energy transfer screening assay for the identification of compounds that are capable of abrogating macrophage-tropic HIV-1 cell fusion
US6265184B1 (en) 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
US7118859B2 (en) 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US6344545B1 (en) * 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US7858298B1 (en) 1996-04-01 2010-12-28 Progenics Pharmaceuticals Inc. Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
EP0915969A4 (de) 1996-04-02 2002-04-17 Progenics Pharm Inc Unterdrückung der infektion von cd4+ zellen durch hiv
EP0906424A2 (de) * 1996-04-26 1999-04-07 Incyte Pharmaceuticals, Inc. Kombinierte lymphozytrezeptoren (mmlr-ccr), von der chemokin rezeptoren familie
US5939320A (en) * 1996-05-20 1999-08-17 New York University G-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
US6258527B1 (en) 1996-05-20 2001-07-10 The Aaron Diamond Aids Research Center Methods of identifying g-coupled receptors associated with macrophage-trophic HIV, and diagnostic and therapeutic uses thereof
EP0975749A2 (de) 1996-05-28 2000-02-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Cc chemokine receptor 5, antikörper dazu, transgene tieren
US20040086528A1 (en) * 1996-06-14 2004-05-06 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting HIV-1 infection
JP4183754B2 (ja) * 1996-06-14 2008-11-19 プロジェニクス・ファーマスーティカルス・インコーポレーテッド Ｈｉｖ―１感染を阻害するためのケモカイン受容体の使用
US6057102A (en) * 1996-08-08 2000-05-02 The Aaron Diamond Aids Research Center HIV coreceptor mutants
WO1998005798A1 (en) * 1996-08-08 1998-02-12 The Aaron Diamond Aids Research Center Hiv coreceptor mutants
US6388055B1 (en) 1996-10-03 2002-05-14 Smithkline Beecham Corporation Mouse CC-CKR5 receptor polypeptide
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
WO1998034945A1 (en) * 1997-02-06 1998-08-13 Epoch Pharmaceuticals, Inc. Targeted modification of the ccr-5 gene
US6153431A (en) * 1997-05-30 2000-11-28 Fond Mondiale Rech & Prev Sida Human immunodeficiency virus co-receptor variants associated with resistance to virus infection
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6204024B1 (en) 1997-09-12 2001-03-20 Akzo Nobel N.V. CCR5 RNA transcription based amplification assay
FR2771423A1 (fr) * 1997-11-21 1999-05-28 Transgene Sa Vecteurs permettant d'inhiber ou retarder la liaison d'un virus d'immunodeficience et/ou sa penetration dans une cellule cible
US6100087A (en) * 1998-03-11 2000-08-08 City Of Hope Ribozymes targeted to human CCR5 mRNA
US20040228869A1 (en) * 1998-12-16 2004-11-18 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
US20080015348A1 (en) * 1998-12-16 2008-01-17 Progenics Pharmaceuticals, Inc. Nucleic acids encoding polypeptides of anti-CCR5 antibodies
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6329159B1 (en) * 1999-03-11 2001-12-11 Millennium Pharmaceuticals, Inc. Anti-GPR-9-6 antibodies and methods of identifying agents which modulate GPR-9-6 function
US7304127B2 (en) * 1999-08-27 2007-12-04 United States Of America As Represented By The Secretary, Department Of Health And Human Services Polypeptides that bind HIV gp120 and related nucleic acids, antibodies, compositions, and methods of use
AU6104699A (en) * 1999-09-23 2001-04-24 Isis Innovation Limited Susceptibility gene for inflammatory bowel disease
CA2389196A1 (en) * 1999-10-28 2001-05-03 Nissui Pharmaceutical Co., Ltd. Cyclic peptides and aids vaccines
AU2001243145A1 (en) * 2000-02-09 2001-08-20 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7060273B2 (en) * 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
JP2005508173A (ja) * 2001-11-07 2005-03-31 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ２３２、２０５９、１０６３０、１２８４８、１３８７５、１４３９５、１４６１８、１７６９２または５８８７４を使用する血液障害を処置するための方法および組成物
US20030104496A1 (en) * 2001-11-30 2003-06-05 Cytokinetics, Inc. Novel motor protein of P. falciparum and methods for its use
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
CA2559809A1 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Antibodies against human g-protein chemokine receptor (ccr5) hdgnr10
US20060068426A1 (en) * 2004-08-20 2006-03-30 Tam James P Cyclic peptides and antibodies thereof
KR20080035653A (ko) * 2005-07-22 2008-04-23 프로제닉스 파머슈티컬스, 인코포레이티드 Ｈｉｖ―１ 감염 환자에서 바이러스 부하를 감소시키는방법
WO2007016372A2 (en) * 2005-07-28 2007-02-08 Eden Biotech Ltd. Method for regenerating an immune system
EP2025762A3 (de) 2006-01-17 2009-09-30 Health Research Inc. Heteroduplex-Trackingassay
JP4569477B2 (ja) 2006-01-17 2010-10-27 パナソニック株式会社 スピーカ
AR065369A1 (es) 2007-02-19 2009-06-03 Novartis Ag Derivados de ciclohexil - amida del acido aril- carboxilico
US20080283557A1 (en) * 2007-05-17 2008-11-20 Julianne Desautels Spout for food stuff container
US20090074766A1 (en) * 2007-09-14 2009-03-19 Ketas Thomas J Methods of inhibiting HIV-2 infection
EP2425001A4 (de) 2009-04-30 2012-11-14 Univ California Anti-hiv-kombinationsvektoren, targeting-vektoren und anwendungsverfahren
WO2014026053A1 (en) 2012-08-09 2014-02-13 The Regents Of The University Of California Cd25 pre-selective combination anti-hiv vectors, targeting vectors, and methods of use
JP2016522679A (ja) * 2013-04-04 2016-08-04 プレジデント アンド フェローズ オブ ハーバード カレッジ ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
JP2016528890A (ja) 2013-07-09 2016-09-23 プレジデント アンド フェローズ オブ ハーバード カレッジ ＣＲＩＳＰＲ／Ｃａｓ系を用いるゲノム編集の治療用の使用
EP3215623A4 (de) 2014-11-06 2018-09-26 President and Fellows of Harvard College Zellen ohne b2m-oberflächenexpression und verfahren zur allogenen verabreichung derartiger zellen
CA2988854A1 (en) 2015-05-08 2016-11-17 President And Fellows Of Harvard College Universal donor stem cells and related methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105741A0 (en) * 1992-05-22 1993-09-22 Genta Inc Pharmaceutical compositions for treating cellular hyperproliferation using interleukin-1 inhibitory compounds
JP3532570B2 (ja) * 1994-01-13 2004-05-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 哺乳類単球化学誘引物質タンパク質レセプター
US5545549A (en) * 1994-02-03 1996-08-13 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
GB9501683D0 (en) * 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
AU2663295A (en) * 1995-06-06 1996-12-24 Human Genome Sciences, Inc. Human g-protein chemokine receptor hdgnr10
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US6265184B1 (en) 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
EP0906424A2 (de) * 1996-04-26 1999-04-07 Incyte Pharmaceuticals, Inc. Kombinierte lymphozytrezeptoren (mmlr-ccr), von der chemokin rezeptoren familie
EP0975749A2 (de) * 1996-05-28 2000-02-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Cc chemokine receptor 5, antikörper dazu, transgene tieren
US5928881A (en) 1996-07-11 1999-07-27 Smithkline Beecham Corporation Method of identifying agonists and antagonist for CC-CKR5 receptor
US6153431A (en) * 1997-05-30 2000-11-28 Fond Mondiale Rech & Prev Sida Human immunodeficiency virus co-receptor variants associated with resistance to virus infection
US6057182A (en) * 1997-09-05 2000-05-02 Sarnoff Corporation Hydrogenation of polysilicon thin film transistors

Also Published As

Publication number Publication date
US20040110127A1 (en) 2004-06-10
DK1482042T3 (da) 2009-06-15
US6930174B2 (en) 2005-08-16
US20020106742A1 (en) 2002-08-08
US6448375B1 (en) 2002-09-10
PT883687E (pt) 2005-02-28
DE69739366D1 (de) 2009-05-28
JP4117904B2 (ja) 2008-07-16
DK0883687T3 (da) 2005-03-07
US6800447B2 (en) 2004-10-05
US20040161739A1 (en) 2004-08-19
EP1199360A2 (de) 2002-04-24
US7285390B2 (en) 2007-10-23
US20020110870A1 (en) 2002-08-15
EP1482042B1 (de) 2009-04-15
EP1482042A1 (de) 2004-12-01
ES2227672T3 (es) 2005-04-01
DE69731373D1 (de) 2004-12-02
ATE280826T1 (de) 2004-11-15
CA2247989C (en) 2010-12-14
JP2008179639A (ja) 2008-08-07
CA2247989A1 (en) 1997-09-04
EP0883687A2 (de) 1998-12-16
ES2325073T3 (es) 2009-08-25
EP2034023A1 (de) 2009-03-11
DE69731373T2 (de) 2006-03-09
EP0883687B1 (de) 2004-10-27
US20020110805A1 (en) 2002-08-15
WO1997032019A2 (en) 1997-09-04
JP2000505301A (ja) 2000-05-09
WO1997032019A3 (en) 1997-10-23
US6692938B2 (en) 2004-02-17
EP1199360A3 (de) 2002-05-02

Similar Documents

Publication Publication Date Title
DE69739366D1 (de) Aktive und inactive CC-Chemokinrezeptoren und Nukleinsäuremoleküle, die für diesen Rezeptor kodieren
ATE318903T1 (de) Modulatoren für die regenerierung von gewebe
TR200100056T2 (tr) Nörotrofik faktörler
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
IL125124A0 (en) Dimeric forms of the protein fapalpha and uses thereof
PT938502E (pt) Metodo selectivo por acilacao
ATE397062T1 (de) Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten
FI972384L (fi) Uudet dipeptidiset p-amidinobentsyyliamidit, jotka sisältävät N-terminaalisia sulfonyyli- tai amidinosulfonyyliryhmiä
ATE505549T1 (de) Männliche fertilitätvermittelnde nukleotidsequenzen und deren verwendung
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
ATE385517T1 (de) Interferon ähnliche moleküle, und deren verwendungen
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen
CO4480058A1 (es) Genes codificantes y procedimiento de expresion de una nueva enzima: ftalil amidasa
GB9811221D0 (en) Bacterial-pheromones and uses therefor
PE20000759A1 (es) Gen de la citocroma oxidasa de hidroquinona del tipo bd
DE69739071D1 (de) Menschliche tak1 und für diese kodierende dna
PE20399A1 (es) Muteina ob
GB9416536D0 (en) Orphan receptor
MXPA01004291A (es) Antigenos de chlamydia y fragmentos de acido desoxirribonucleico correspondientes y usos de los mismos.
ATE315646T1 (de) Leukocyten-aktivierender faktor
ATE283356T1 (de) Tab1 protein und dafür kodierende dna
DE3777359D1 (de) Aminosaeuresequenz des menschlichen alpha 2-plasmininhibitors und cdns sowie diese aminosaeuresequenz codierende genomische dns.
ATE332923T1 (de) Cr1 fragmente und deren verwendung
DE69530295D1 (de) Leishmania hauptprotein, dafür kodierende nukleinsaüre und verwendungen davon
MX9709596A (es) Adn catal ??tico.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1482042

Country of ref document: EP